Literature DB >> 24581741

XYLT1 mutations in Desbuquois dysplasia type 2.

Catherine Bui1, Céline Huber1, Beyhan Tuysuz2, Yasemin Alanay3, Christine Bole-Feysot4, Jules G Leroy5, Geert Mortier6, Patrick Nitschke7, Arnold Munnich1, Valérie Cormier-Daire8.   

Abstract

Desbuquois dysplasia (DBQD) is a severe condition characterized by short stature, joint laxity, and advanced carpal ossification. Based on the presence of additional hand anomalies, we have previously distinguished DBQD type 1 and identified CANT1 (calcium activated nucleotidase 1) mutations as responsible for DBQD type 1. We report here the identification of five distinct homozygous xylosyltransferase 1 (XYLT1) mutations in seven DBQD type 2 subjects from six consanguineous families. Among the five mutations, four were expected to result in loss of function and a drastic reduction of XYLT1 cDNA level was demonstrated in two cultured individual fibroblasts. Because xylosyltransferase 1 (XT-I) catalyzes the very first step in proteoglycan (PG) biosynthesis, we further demonstrated in the two individual fibroblasts a significant reduction of cellular PG content. Our findings of XYLT1 mutations in DBQD type 2 further support a common physiological basis involving PG synthesis in the multiple dislocation group of disorders. This observation sheds light on the key role of the XT-I during the ossification process.
Copyright © 2014 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24581741      PMCID: PMC3951945          DOI: 10.1016/j.ajhg.2014.01.020

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  40 in total

1.  Heparan sulfate enhances the self-renewal and therapeutic potential of mesenchymal stem cells from human adult bone marrow.

Authors:  Torben Helledie; Christian Dombrowski; Bina Rai; Zophia X H Lim; Ian Lee Hock Hin; David A Rider; Gary S Stein; Wanjin Hong; Andre J van Wijnen; James H Hui; Victor Nurcombe; Simon M Cool
Journal:  Stem Cells Dev       Date:  2012-01-18       Impact factor: 3.272

Review 2.  Redefining the progeroid form of Ehlers-Danlos syndrome: report of the fourth patient with B4GALT7 deficiency and review of the literature.

Authors:  Michael H Guo; Joan Stoler; Julian Lui; Ola Nilsson; Diana W Bianchi; Joel N Hirschhorn; Andrew Dauber
Journal:  Am J Med Genet A       Date:  2013-08-16       Impact factor: 2.802

3.  IMPAD1 mutations in two Catel-Manzke like patients.

Authors:  Mathilde Nizon; Yasemin Alanay; Beyhan Tuysuz; Pelin Ozlem Simsek Kiper; David Geneviève; David Sillence; Celine Huber; Arnold Munnich; Valérie Cormier-Daire
Journal:  Am J Med Genet A       Date:  2012-08-06       Impact factor: 2.802

4.  The missing "link": an autosomal recessive short stature syndrome caused by a hypofunctional XYLT1 mutation.

Authors:  Julia Schreml; Burak Durmaz; Ozgur Cogulu; Katharina Keupp; Filippo Beleggia; Esther Pohl; Esther Milz; Mahmut Coker; Sema Kalkan Ucar; Gudrun Nürnberg; Peter Nürnberg; Joachim Kuhn; Ferda Ozkinay
Journal:  Hum Genet       Date:  2013-08-27       Impact factor: 4.132

5.  Mutations in B3GALT6, which encodes a glycosaminoglycan linker region enzyme, cause a spectrum of skeletal and connective tissue disorders.

Authors:  Masahiro Nakajima; Shuji Mizumoto; Noriko Miyake; Ryo Kogawa; Aritoshi Iida; Hironori Ito; Hiroshi Kitoh; Aya Hirayama; Hiroshi Mitsubuchi; Osamu Miyazaki; Rika Kosaki; Reiko Horikawa; Angeline Lai; Roberto Mendoza-Londono; Lucie Dupuis; David Chitayat; Andrew Howard; Gabriela F Leal; Denise Cavalcanti; Yoshinori Tsurusaki; Hirotomo Saitsu; Shigehiko Watanabe; Ekkehart Lausch; Sheila Unger; Luisa Bonafé; Hirofumi Ohashi; Andrea Superti-Furga; Naomichi Matsumoto; Kazuyuki Sugahara; Gen Nishimura; Shiro Ikegawa
Journal:  Am J Hum Genet       Date:  2013-05-09       Impact factor: 11.025

6.  Defective initiation of glycosaminoglycan synthesis due to B3GALT6 mutations causes a pleiotropic Ehlers-Danlos-syndrome-like connective tissue disorder.

Authors:  Fransiska Malfait; Ariana Kariminejad; Tim Van Damme; Caroline Gauche; Delfien Syx; Faten Merhi-Soussi; Sandrine Gulberti; Sofie Symoens; Suzanne Vanhauwaert; Andy Willaert; Bita Bozorgmehr; Mohamad Hasan Kariminejad; Nazanin Ebrahimiadib; Ingrid Hausser; Ann Huysseune; Sylvie Fournel-Gigleux; Anne De Paepe
Journal:  Am J Hum Genet       Date:  2013-05-09       Impact factor: 11.025

7.  Forward genetics defines Xylt1 as a key, conserved regulator of early chondrocyte maturation and skeletal length.

Authors:  Emily K Mis; Karel F Liem; Yong Kong; Nancy B Schwartz; Miriam Domowicz; Scott D Weatherbee
Journal:  Dev Biol       Date:  2013-10-23       Impact factor: 3.582

Review 8.  Synthesis and sorting of proteoglycans.

Authors:  K Prydz; K T Dalen
Journal:  J Cell Sci       Date:  2000-01       Impact factor: 5.285

9.  Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis.

Authors:  Mathilde Nizon; Céline Huber; Fabio De Leonardis; Rodolphe Merrina; Antonella Forlino; Mélanie Fradin; Beyhan Tuysuz; Bassam Y Abu-Libdeh; Yasemin Alanay; Beate Albrecht; Lihadh Al-Gazali; Sarenur Yilmaz Basaran; Jill Clayton-Smith; Julie Désir; Harinder Gill; Marie T Greally; Erkan Koparir; Merel C van Maarle; Sara MacKay; Geert Mortier; Jenny Morton; David Sillence; Catheline Vilain; Ian Young; Klaus Zerres; Martine Le Merrer; Arnold Munnich; Carine Le Goff; Antonio Rossi; Valérie Cormier-Daire
Journal:  Hum Mutat       Date:  2012-05-22       Impact factor: 4.878

Review 10.  Nosology and classification of genetic skeletal disorders: 2010 revision.

Authors:  Matthew L Warman; Valerie Cormier-Daire; Christine Hall; Deborah Krakow; Ralph Lachman; Martine LeMerrer; Geert Mortier; Stefan Mundlos; Gen Nishimura; David L Rimoin; Stephen Robertson; Ravi Savarirayan; David Sillence; Juergen Spranger; Sheila Unger; Bernhard Zabel; Andrea Superti-Furga
Journal:  Am J Med Genet A       Date:  2011-03-15       Impact factor: 2.802

View more
  45 in total

Review 1.  Advances in Skeletal Dysplasia Genetics.

Authors:  Krista A Geister; Sally A Camper
Journal:  Annu Rev Genomics Hum Genet       Date:  2015-04-22       Impact factor: 8.929

2.  Short stature, accelerated bone maturation, and early growth cessation due to heterozygous aggrecan mutations.

Authors:  Ola Nilsson; Michael H Guo; Nancy Dunbar; Jadranka Popovic; Daniel Flynn; Christina Jacobsen; Julian C Lui; Joel N Hirschhorn; Jeffrey Baron; Andrew Dauber
Journal:  J Clin Endocrinol Metab       Date:  2014-04-24       Impact factor: 5.958

3.  A Report of Novel STIM1 Deficiency and 6-Year Follow-Up of Two Previous Cases Associated with Mild Immunological Phenotype.

Authors:  Laura Rice; Claire Stockdale; Ian Berry; Sean O'Riordan; Karen Pysden; Rashida Anwar; Roger Rushambuza; Moira Blyth; Sonal Srikanth; Yousang Gwack; Yasser M El-Sherbiny; Clive Carter; Sinisa Savic
Journal:  J Clin Immunol       Date:  2019-04-04       Impact factor: 8.317

4.  Skeletal dysplasia in a consanguineous clan from the island of Nias/Indonesia is caused by a novel mutation in B3GAT3.

Authors:  Birgit S Budde; Shuji Mizumoto; Ryo Kogawa; Christian Becker; Janine Altmüller; Holger Thiele; Franz Rüschendorf; Mohammad R Toliat; Gerrit Kaleschke; Johannes M Hämmerle; Wolfgang Höhne; Kazuyuki Sugahara; Peter Nürnberg; Ingo Kennerknecht
Journal:  Hum Genet       Date:  2015-04-19       Impact factor: 4.132

5.  GGC Repeat Expansion and Exon 1 Methylation of XYLT1 Is a Common Pathogenic Variant in Baratela-Scott Syndrome.

Authors:  Amy J LaCroix; Deborah Stabley; Rebecca Sahraoui; Margaret P Adam; Michele Mehaffey; Kelly Kernan; Candace T Myers; Carrie Fagerstrom; George Anadiotis; Yassmine M Akkari; Katherine M Robbins; Karen W Gripp; Wagner A R Baratela; Michael B Bober; Angela L Duker; Dan Doherty; Jennifer C Dempsey; Daniel G Miller; Martin Kircher; Michael J Bamshad; Deborah A Nickerson; Heather C Mefford; Katia Sol-Church
Journal:  Am J Hum Genet       Date:  2018-12-13       Impact factor: 11.025

6.  Novel and recurrent XYLT1 mutations in two Turkish families with Desbuquois dysplasia, type 2.

Authors:  Long Guo; Nursel H Elcioglu; Aritoshi Iida; Yasemin K Demirkol; Seda Aras; Naomichi Matsumoto; Gen Nishimura; Noriko Miyake; Shiro Ikegawa
Journal:  J Hum Genet       Date:  2016-11-24       Impact factor: 3.172

7.  Xylose phosphorylation functions as a molecular switch to regulate proteoglycan biosynthesis.

Authors:  Jianzhong Wen; Junyu Xiao; Meghdad Rahdar; Biswa P Choudhury; Jixin Cui; Gregory S Taylor; Jeffrey D Esko; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-20       Impact factor: 11.205

Review 8.  Biosynthesis of glycosaminoglycans: associated disorders and biochemical tests.

Authors:  Florin Sasarman; Catalina Maftei; Philippe M Campeau; Catherine Brunel-Guitton; Grant A Mitchell; Pierre Allard
Journal:  J Inherit Metab Dis       Date:  2015-12-21       Impact factor: 4.982

9.  PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia.

Authors:  Asbjørg Stray-Pedersen; Paul H Backe; Hanne S Sorte; Lars Mørkrid; Niti Y Chokshi; Hans Christian Erichsen; Tomasz Gambin; Katja B P Elgstøen; Magnar Bjørås; Marcin W Wlodarski; Marcus Krüger; Shalini N Jhangiani; Donna M Muzny; Ankita Patel; Kimiyo M Raymond; Ghadir S Sasa; Robert A Krance; Caridad A Martinez; Shirley M Abraham; Carsten Speckmann; Stephan Ehl; Patricia Hall; Lisa R Forbes; Else Merckoll; Jostein Westvik; Gen Nishimura; Cecilie F Rustad; Tore G Abrahamsen; Arild Rønnestad; Liv T Osnes; Torstein Egeland; Olaug K Rødningen; Christine R Beck; Eric A Boerwinkle; Richard A Gibbs; James R Lupski; Jordan S Orange; Ekkehart Lausch; I Celine Hanson
Journal:  Am J Hum Genet       Date:  2014-06-12       Impact factor: 11.025

10.  Exome sequencing reveals two novel compound heterozygous XYLT1 mutations in a Polish patient with Desbuquois dysplasia type 2 and growth hormone deficiency.

Authors:  Aleksander Jamsheer; Ewelina M Olech; Kazimierz Kozłowski; Marek Niedziela; Anna Sowińska-Seidler; Monika Obara-Moszyńska; Anna Latos-Bieleńska; Marek Karczewski; Tomasz Zemojtel
Journal:  J Hum Genet       Date:  2016-03-31       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.